Version 2.11 of the SYNTAX Score calculator contains the latest four-year SYNTAX trial results. The SYNTAX Score website now uses this version.

Unlike the online calculator, the standalone calculator is not automatically updated. Be sure to check our website regularly to ensure you are using the latest calculator version. The current version can be downloaded here:

SYNTAX Score Calculator 2.11

For a detailed changelog select read more below.

Version 2.1 of the SYNTAX Score calculator contains the latest three-year SYNTAX trial results. In addition, some changes were made in scoring total occlusions and the definition of diffusely diseased and narrowed sections. The SYNTAX Score website now uses this version.

Unlike the online calculator, the standalone calculator is not automatically updated. Be sure to check our website regularly to ensure you are using the latest calculator version.

For a detailed changelog select read more below.

Pieter Kappetein, MD, PhD presented the three-year results of the SYNTAX trial at the European Association for Cardio-Thoracic Surgery Meeting, Geneva on September 12th, 2010. Key findings included:

• In the SYNTAX randomized patients, 3-year MACCE rates remained significantly higher for PCI than CABG, mainly driven by higher repeat revascularization in the PCI arm.
• MACCE rates at 3 years not significantly different for patients with a low (0-22) baseline SYNTAX Score; for patients with intermediate (23-32) or high SYNTAX scores (³33), MACCE was increased at 3 years in patients treated with PCI

The 3-year SYNTAX results suggest that CABG remains the standard of care for patients with complex disease (intermediate or high SYNTAX Scores); however, PCI may be an acceptable alternative revascularization method to CABG when treating patients with less complex (lower SYNTAX Score) disease.

The full presentation can be viewed or downloaded here:

Presentation: SYNTAX 3 year results, EACTS 2010

Pieter Kappetein, MD, PhD presented the two-year results of the SYNTAX trial at the European Society of Cardiology Meeting, Barcelona on September 2nd, 2009. SYNTAX was featured in a Clinical Trial webcast. Key findings included:

• In the SYNTAX randomized patients, 2-year MACCE rates remained significantly higher for PCI than CABG, mainly driven by higher repeat revascularization in the PCI arm.
• MACCE rates at 2 years not significantly different for patients with a low (0-22) or intermediate (23-32) baseline SYNTAX Score treated with either PCI or CABG; for patients with high SYNTAX Scores (≥33), MACCE continued to be increased at 2 years in patients treated with PCI compared with CABG
• In the predefined subgroups of patients with either 3VD or LM disease:
  • In the LM group, safety outcomes and MACCE rates were similar for PCI and CABG, but the 2-year revascularization rate was lower in the CABG group.
  • Safety outcomes (death/CVA/MI) in the 3VD group were similar for PCI and CABG, but the 2-year revascularization and MACCE rates favored CABG. 

The full presentation can be viewed or downloaded here:

Presentation: SYNTAX 2 year results, ESC 2009